HBVCure New
Meeting category
Date(s)
9 Nov 2016
Location
Toronto, Canada
Organizer

International Workshop on HBV Cure 2016

Related Enduring Materials

Enduring Materials

 Wednesday, 9 November 2016

Session 1 -
Chairs
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
Scott Fung, MD, FRCPC
Toronto General Hospital, Toronto, Canada
Current Status of HBV Therapy
Pietro Lampertico, MD, PhD
University of Milan, Italy
Why do we need new treatments and what is our definition of cure?
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Session 2 -
Chairs
Stephen Locarnini
Stephen Locarnini, BSc, PhD, MBBS, FRC
Victorian Infectious Diseases Reference Laboratory Melbourne, Australia
Charles Boucher, MD, PhD
Erasmus Medical Center, The Netherlands
New Treatment Options: Virological Approach
- Entry inhibition
Stephan Urban
Stephan Urban, PhD
Heidelberg University, Germany
- CCC – DNA inhibition
Massimo Levrero, MD
Hopital de la Croix-Rousse, France
- Small interfering RNA’s
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Victorian Infectious Diseases Reference Laboratory
- New Nucleoside Analogue & Capsid inhibition
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
- Assembly and Secretion Inhibitors
Tim Block
Tim Block, PhD
Hepatitis B Foundation, Doylestown, USA
Session 3 -
Chairs
Mala Maini, MD, PhD
University College London, United Kingdom
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
How does HBV interact with the immune system?
Robert Thimme
Robert Thimme, MD
University of Freiburg, Germany
New Treatment options: Immunomodulatory Agents
- Therapeutic Vaccines
Kyong-Mi Chang
Kyong-Mi Chang, MD
University of Pennsylvania, Philadelphia, USA
- Adaptive Immunity: - PDL Blockers
Mala Maini, MD, PhD
University College London, United Kingdom
- Innate Immunity
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
Session 4 -
Chairs
Stephan Urban
Stephan Urban, PhD
Heidelberg University, Heidelberg, Germany
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
How to combine new treatments? Scientific approach
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
How to combine new treatments? Clinical approach
Marion Peters, MD
Northwestern University, United States
Roundtable discussion "trial design, treatment endpoints and regulatory approach”.
Overview
Welcome

The International HBV Cure Workshop took place on Wednesday 9 November 2016 in Toronto, Canada.

We welcomed 82 unique participants from 17 different countries at this successful 3rd edition of the International Workshop on Hepatitis B Cure.

The Organizing Committee would like to thank all invited speakers and participants for their contribution to this meeting. 

We would like to thank our supporters Gilead, Assembly Biosciences, Arbutus Biopharma, Arrowhead, Humanity and Health, Medlmumme, Roche, Siemens Healthineers, MSD, Janssen, for making this event possible.

Kind regards,

Chairs 2016

Chairs 2016
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Background

More than 250 million people are chronically infected with hepatitis B (HBV) around the globe. The purpose of the program is to inform the participants about the developments in the possibilities to find a cure for HBV. The meeting will be highly interactive with input from experts out of the arena of basic, translational and clinical HBV research.

The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available are providing great hopes for decreasing the burden of the disease, simplifying treatment and ultimately curing and eradicating HBV infection.

In order to optimize curative treatment for HBV, outstanding speakers from around the globe will share the newest therapeutic options for viral hepatitis and experts will discuss the path forward to cure this deadly disease, leading to liver cirrhosis and liver cancer. Questions on which end points to use in therapeutic trials and how to combine different agents targeting the virus and/or immune system will be extensively discussed.

This workshop also brings together global inter-disciplinary experts to provide a framework for how academia and industry should could collaborate to achieve the goal of curing hepatitis B.

Endorsers
Language